Program
HRS-6209
A development code. Also written as “HRS-6209 in Combination with HRS-1358”, “HRS-6209 + Letrozole” and “HRS-6209 in Combination with Fulvestrant”.
In Jiangsu HengRui Medicine's pipeline, CDK4
. Its studies are mostly in Breast Neoplasms, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 77 open or running | phase 3since Oct 14, 2026 | Feb 23, 2023 | Dec 2026phase 2 · NCT06974929 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-6209
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 23, 2023First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05781048 · 56 enrolled · China
- Aug 1, 2024Phase 2 study in Breast NeoplasmsNCT06555068 · 528 planned · China
- Nov 6, 2024Phase 2 study in Breast NeoplasmsNCT06679036 · 300 planned · China
- May 8, 2025Phase 2 study in Breast NeoplasmsNCT06974929 · 80 planned · China
- Dec 28, 2025Phase 1 study in Breast NeoplasmsNCT07358377 · 15 planned · Australia
- May 20, 2026Phase 1 study in Breast NeoplasmsNCT07610148 · 21 enrolled · China
- Oct 14, 2026Phase 3 study in Breast NeoplasmsPhase 3 reachedNCT07894328 · 1,050 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Breast NeoplasmsNCT06974929
- Dec 30, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT05781048
- Apr 10, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07358377
- Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06555068
TargetBeta
“CDK4”the company's pipeline, read by Claude · source
Other programs on CDK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 49 |
| palbociclibrule | Pfizer | phase 4 | 36 |
| trilaciclibrule | Pharmacosmos | phase 4 | 14 |
| atirmociclib | Pfizer | phase 3 | 17 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| CDK4 Inhibitor BGB-43395rule | BeOne Medicines | phase 3 | 4 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
| TSL2109rule | China Resources Pharmaceutical Group | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07894328Breast Neoplasms · China | 3 | Not yet recruiting | Jul 30, 2031 | 1,050 |
| NCT07610148Breast Neoplasms · China | 1 | Active, not recruiting | Sep 2026 | 21 |
| NCT07358377Breast Neoplasms · Australia | 1 | Recruiting | Apr 10, 2027 | 15 |
| NCT06974929Breast Neoplasms · China | 2 | Recruiting | Dec 2026 | 80 |
| NCT06679036Breast Neoplasms · China | 2 | Recruiting | Oct 30, 2026 | 300 |
| NCT06555068Breast Neoplasms · China | 2 | Recruiting | Dec 2027 | 528 |
| NCT05781048Advanced Solid Tumors · China | 1 | Active, not recruiting | Dec 30, 2026 | 56 |
How it is read
Names in the registry
- “HRS-6209 in Combination with HRS-1358”, 2 entries
- “HRS-6209”, 2 entries
- “HRS-6209 + Letrozole”, 1 entry
- “HRS-6209 in Combination with Fulvestrant”, 1 entry
- “HRS-6209 in Combination with Letrozole”, 1 entry
Codes read as this program: HRS6209.
Conditions, from the studies’ own filings
- Breast Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.